Business

Announcement on Voluntary Disclosure of Completion of the First Patient Enrollment and Dosing in the Phase II Clinical Trial of SGC001 Innovative Drug by a Subsidiary

Announcement on Voluntary Disclosure of Completion of the First Patient Enrollment and Dosing in the Phase II Clinical Trial of SGC001 Innovative Drug by a Subsidiary

articleBeijing Hotgen Biotech Co. Ltd. Class AMarch 10, 20264/news/announcement-on-voluntary-disclosure-of-completion-of-the-first-patient-enrollment-and-dosing-in-the-phase-ii-clinical-trial-of-sgc001-innovative-drug-by-a-subsidiary
Announcement on Voluntary Disclosure of Completion of the First Patient Enrollment and Dosing in the Phase II Clinical Trial of SGC001 Innovative Drug by a Subsidiary

About this update from Beijing Hotgen Biotech Co. Ltd. Class A

Announcement on Voluntary Disclosure of Completion of the First Patient Enrollment and Dosing in the Phase II Clinical Trial of SGC001 Innovative Drug by a Subsidiary The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Beijing Hotgen Biotech Co. Ltd. Class A